Tenaya Therapeutics Outlines 2026 Strategy Including Regulatory Alignment for Gene Therapy Programs, Key Clinical Data Milestones, and Extended Funding Through Mid-2027
I'm PortAI, I can summarize articles.
Tenaya Therapeutics Inc. has outlined its strategic priorities for 2026, focusing on regulatory alignment for its TN-201 and TN-401 gene therapy programs. The company plans to provide long-term follow-up data from the MyPEAK-1 trial and report one-year data from the RIDGE-1 study in the first half of 2026. Updates on pivotal studies are expected in the second half of 2026, supported by recently raised capital to advance clinical programs.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments